Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RYTM

Rhythm Pharmaceuticals Inc.

Sep 06 • 04:00PM ET

49.25

Dollar change +0.98
Percentage change 2.03	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF XBI IWO IBB SCHA VTWO VHT DWAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.37	Insider Own	10.79%	Shs Outstand	59.43M	Perf Week	6.83%
Market Cap	3.01B	Forward P/E	-	EPS next Y	-2.73	Insider Trans	-3.83%	Shs Float	54.54M	Perf Month	13.06%
Income	-260.72M	PEG	-	EPS next Q	-0.80	Inst Own	104.35%	Short Float	18.11%	Perf Quarter	24.12%
Sales	101.78M	P/S	29.58	EPS this Y	-38.37%	Inst Trans	21.84%	Short Ratio	21.21	Perf Half Y	18.19%
Book/sh	0.64	P/B	76.48	EPS next Y	38.42%	ROA	-75.00%	Short Interest	9.88M	Perf Year	92.31%
Cash/sh	5.22	P/C	9.43	EPS next 5Y	-9.00%	ROE	-234.10%	52W Range	20.97 - 53.92	Perf YTD	7.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.04%	ROI	-89.54%	52W High	-8.66%	Beta	2.06
Dividend TTM	-	Quick Ratio	6.31	Sales past 5Y	175.40%	Gross Margin	88.01%	52W Low	134.86%	ATR (14)	2.18
Dividend Ex-Date	-	Current Ratio	6.53	EPS Y/Y TTM	-32.68%	Oper. Margin	-260.93%	RSI (14)	58.18	Volatility	4.43% 4.35%
Employees	226	Debt/Eq	6.42	Sales Y/Y TTM	132.57%	Profit Margin	-256.15%	Recom	1.22	Target Price	59.44
Option/Short	Yes / Yes	LT Debt/Eq	6.40	EPS Q/Q	33.02%	Payout	-	Rel Volume	0.95	Prev Close	48.27
Sales Surprise	1.00%	EPS Surprise	22.42%	Sales Q/Q	51.28%	Earnings	Aug 06 BMO	Avg Volume	465.58K	Price	49.25
SMA20	6.26%	SMA50	6.26%	SMA200	15.53%	Trades		Volume	443,048	Change	2.03%

Date	Action	Analyst	Rating Change	Price Target Change
May-08-24	Downgrade	BofA Securities	Buy → Neutral	$49 → $42
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$29 → $55
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy	$22 → $27
Jan-18-23	Resumed	Canaccord Genuity	Buy	$52
Aug-08-22	Upgrade	Goldman	Neutral → Buy	$28
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral	$8 → $20
Jun-17-22	Reiterated	Needham	Buy	$40 → $25
Mar-02-22	Resumed	Stifel	Buy	$23
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy	$15
Dec-08-21	Initiated	Wells Fargo	Overweight	$30
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$50 → $15
Sep-14-21	Resumed	Goldman	Neutral	$14
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-04-21	Downgrade	BofA Securities	Neutral → Underperform	$33 → $17
Nov-30-20	Downgrade	BofA Securities	Buy → Neutral	$27 → $33
Jan-08-20	Initiated	Goldman	Sell	$18
Jul-12-19	Upgrade	Stifel	Hold → Buy	$34
Jul-08-19	Initiated	Canaccord Genuity	Buy	$35
Mar-13-19	Initiated	Ladenburg Thalmann	Buy	$43
Sep-07-18	Resumed	Morgan Stanley	Overweight

Show Previous Ratings

Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
Aug-26-24 08:02AM	Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE (setmelanotide) in Patients as Young as 2 years old (GlobeNewswire) +8.41%
08:00AM	Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September (GlobeNewswire)
Aug-13-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Aug-06-24 08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-31-24 09:10AM	Rhythm Pharmaceuticals Announces European Commission Expands IMCIVREE (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old (GlobeNewswire)
Jul-23-24 08:00AM	Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity (GlobeNewswire)
07:30AM	Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 (GlobeNewswire)
Jul-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +5.00% +7.34%
Jul-08-24 08:00AM	Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Jun-28-24 08:00AM	Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency (GlobeNewswire)
Jun-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +5.36%
Jun-03-24 04:02PM	Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 (GlobeNewswire) +6.08%
08:02AM	Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference (GlobeNewswire)
04:00AM	Loading…
May-22-24 04:00AM	Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for IMCIVREE (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome (GlobeNewswire)
May-09-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
May-08-24 10:51AM	Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:06AM	Rhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ... (GuruFocus.com)
May-07-24 10:34PM	Q1 2024 Rhythm Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -10.32%
02:52PM	The 3 Best Nasdaq Stocks to Buy in May 2024 (InvestorPlace)
08:58AM	Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell (MT Newswires)
08:36AM	Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges (GuruFocus.com)
08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
May-06-24 08:00AM	Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting (GlobeNewswire)
Apr-30-24 10:01AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline (Zacks)
Apr-29-24 06:30PM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology (GlobeNewswire)
Apr-28-24 09:20AM	Jim Cramer Portfolio: 11 Latest Stocks to Buy (Insider Monkey)
Apr-24-24 04:01PM	Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (GlobeNewswire)
04:01PM	Loading…
Apr-16-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Apr-01-24 08:00AM	Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing (GlobeNewswire)
Mar-25-24 08:00AM	Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist (GlobeNewswire)
Mar-22-24 07:01PM	Chief Technical Officer Joseph Shulman Sells 18,235 Shares of Rhythm Pharmaceuticals Inc (RYTM) (GuruFocus.com)
Mar-20-24 01:49AM	Insider Sell: Rhythm Pharmaceuticals Inc (RYTM) CEO David Meeker Disposes of 45,494 Shares (GuruFocus.com)
01:49AM	Insider Sell: Chief Technical Officer Joseph Shulman Sells 15,515 Shares of Rhythm ... (GuruFocus.com)
01:49AM	Insider Sell: CFO Hunter Smith Sells 15,515 Shares of Rhythm Pharmaceuticals Inc (RYTM) (GuruFocus.com)
Mar-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Mar-06-24 04:01PM	Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-23-24 12:04PM	Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 10:19PM	Q4 2023 Rhythm Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.73%
08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:35AM	Rhythm Pharmaceuticals Inc (RYTM) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
07:01AM	Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan (GlobeNewswire)
07:00AM	Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Feb-16-24 03:00AM	Chief Technical Officer Joseph Shulman Sells Shares of Rhythm Pharmaceuticals Inc (GuruFocus.com)
Feb-15-24 10:00AM	Rhythm Pharmaceuticals, Inc. (RYTM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-14-24 02:30AM	EVP Yann Mazabraud Sells 2,551 Shares of Rhythm Pharmaceuticals Inc (GuruFocus.com)
Feb-13-24 03:04PM	PRIMECAP Management Reduces Stake in Rhythm Pharmaceuticals (GuruFocus.com) -6.75%
Feb-08-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +7.63%
Feb-07-24 08:00AM	Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome (GlobeNewswire)
Jan-31-24 08:00AM	Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024 (GlobeNewswire)
Jan-12-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Jan-04-24 07:00AM	Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640 (GlobeNewswire)
06:58AM	Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates (GlobeNewswire)
Dec-30-23 11:01AM	Insider Sell: Rhythm Pharmaceuticals CTO Joseph Shulman Sells 12,941 Shares (GuruFocus.com)
Dec-15-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +9.92% -5.11%
Dec-13-23 07:00AM	Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023 (GlobeNewswire)
Dec-08-23 05:05AM	Insider Sell Alert: CFO Hunter Smith Sells 27,026 Shares of Rhythm Pharmaceuticals Inc (RYTM) (GuruFocus.com)
Dec-06-23 07:00AM	Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event (GlobeNewswire)
Nov-17-23 09:03AM	Insider Sell Alert: Joseph Shulman of Rhythm Pharmaceuticals Inc Cashes Out Shares (GuruFocus.com)
Nov-13-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +15.33%
Nov-07-23 08:25AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Rhythm Pharmaceuticals Inc (RYTM) Reports Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Nov-02-23 08:00AM	Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE (setmelanotide) (GlobeNewswire)
Nov-01-23 10:01AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-31-23 10:01AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-25-23 08:00AM	Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 (GlobeNewswire)
Oct-19-23 08:45AM	Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders (PR Newswire)
Oct-17-23 04:01PM	Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek 2023 (GlobeNewswire)
Oct-13-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) -5.52%
Oct-12-23 09:55AM	Wall Street Analysts Believe Rhythm Pharmaceuticals, Inc. (RYTM) Could Rally 53.81%: Here's is How to Trade (Zacks)
Oct-10-23 08:00AM	Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society's Annual Meeting at ObesityWeek (GlobeNewswire)
Sep-22-23 08:00AM	Rhythm Pharmaceuticals Presents New Data at ESPE 2023 (GlobeNewswire)
Sep-19-23 08:01AM	Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity (GlobeNewswire)
Sep-08-23 05:01PM	EVP Jennifer Lee Sells 6,166 Shares of Rhythm Pharmaceuticals Inc (RYTM) (GuruFocus.com)
04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
07:59AM	Rhythm Pharmaceuticals Announces Update to September Conference Participation (GlobeNewswire)
Sep-06-23 07:59AM	Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome (GlobeNewswire)
Aug-28-23 08:00AM	Rhythm Pharmaceuticals to Present at Investor Conferences in September (GlobeNewswire)
Aug-07-23 08:00AM	Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France (GlobeNewswire)
Aug-04-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Aug-03-23 06:07AM	Need To Know: Analysts Are Much More Bullish On Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenues (Simply Wall St.)
Aug-01-23 08:35AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +27.52%
07:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Jul-19-23 08:00AM	Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome (GlobeNewswire)
Jul-18-23 08:00AM	Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023 (GlobeNewswire)
Jul-17-23 06:00AM	Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023 (GlobeNewswire) +5.34%
Jul-14-23 04:40PM	These 2 Biotech Stocks Are Most Likely to Be Acquired, Says Needham and They Have Over 60% Upside Potential (TipRanks)
Jul-13-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Jun-29-23 12:45PM	What Will Amgen Buy Next? (Motley Fool) -8.04%
Jun-17-23 02:01PM	Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023 (GlobeNewswire)
Jun-07-23 08:00AM	Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-06-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Jun-05-23 08:46AM	Investors bid Rhythm Pharmaceuticals (NASDAQ:RYTM) up US$87m despite increasing losses YoY, taking one-year return to 428% (Simply Wall St.)
May-22-23 08:00AM	Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries (GlobeNewswire)
May-09-23 08:11AM	Some Shareholders Feeling Restless Over Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) P/S Ratio (Simply Wall St.)
May-08-23 08:00AM	Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency (GlobeNewswire)
May-05-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cramer Pamela J.	Chief Human Resources Officer	Aug 26 '24	Option Exercise	19.02	3,200	60,864	16,700	Aug 28 04:31 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 26 '24	Sale	50.01	3,200	160,018	13,500	Aug 28 04:31 PM
TETRAULT LYNN A.	Director	Aug 26 '24	Option Exercise	18.99	4,300	81,657	7,300	Aug 28 04:31 PM
TETRAULT LYNN A.	Director	Aug 26 '24	Sale	50.01	4,300	215,029	3,000	Aug 28 04:31 PM
GOOD JENNIFER L	Director	Aug 26 '24	Option Exercise	18.63	14,508	270,322	17,508	Aug 28 04:30 PM
GOOD JENNIFER L	Director	Aug 26 '24	Sale	50.01	14,508	725,526	3,000	Aug 28 04:30 PM
JENNIFER GOOD	Director	Aug 26 '24	Proposed Sale	46.12	35,000	1,614,200		Aug 26 04:27 PM
LYNN TETRAULT393 COMMONWEALTH	Director	Aug 26 '24	Proposed Sale	46.12	7,499	345,854		Aug 26 04:27 PM
PAMELA CRAMER	Officer	Aug 26 '24	Proposed Sale	46.12	7,299	336,630		Aug 26 04:26 PM
TETRAULT LYNN A.	Director	Aug 12 '24	Option Exercise	4.15	10,000	41,500	13,000	Aug 14 04:15 PM
TETRAULT LYNN A.	Director	Aug 12 '24	Sale	44.65	10,000	446,462	3,000	Aug 14 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 09 '24	Option Exercise	19.02	30,771	585,264	62,506	Aug 13 04:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 09 '24	Sale	45.15	49,006	2,212,498	13,500	Aug 13 04:45 PM
LYNN TETRAULT393 COMMONWEALTH	Director	Aug 12 '24	Proposed Sale	45.26	10,000	452,600		Aug 12 04:13 PM
PAMELA CRAMER	Officer	Aug 09 '24	Proposed Sale	45.87	49,006	2,247,905		Aug 09 04:09 PM
Cramer Pamela J.	Chief Human Resources Officer	Jul 29 '24	Sale	49.06	1,395	68,439	31,735	Jul 30 05:09 PM
Shulman Joseph	Chief Technical Officer	Jul 16 '24	Option Exercise	27.35	10,468	286,300	10,498	Jul 18 05:59 PM
Shulman Joseph	Chief Technical Officer	Jul 16 '24	Sale	53.00	10,468	554,817	30	Jul 18 05:59 PM
Shulman Joseph	Chief Technical Officer	Jul 12 '24	Option Exercise	21.38	5,313	113,592	5,343	Jul 16 04:30 PM
Shulman Joseph	Chief Technical Officer	Jul 12 '24	Sale	50.01	5,313	265,725	30	Jul 16 04:30 PM
Shulman Joseph	Chief Technical Officer	May 09 '24	Option Exercise	6.80	3,984	27,091	4,014	May 13 04:21 PM
Shulman Joseph	Chief Technical Officer	May 09 '24	Sale	38.47	3,984	153,259	30	May 13 04:21 PM
German Christopher Paul	Corporate Controller & CAO	Apr 02 '24	Sale	41.76	368	15,368	795	Apr 03 08:00 PM
Shulman Joseph	Chief Technical Officer	Mar 21 '24	Sale	40.34	18,235	735,600	30	Mar 22 04:55 PM
Lee Jennifer Kayden	EVP, Head of North America	Mar 20 '24	Sale	38.77	18,235	707,005	6,852	Mar 22 04:16 PM
Smith Hunter C	Chief Financial Officer	Mar 19 '24	Sale	39.22	15,515	608,498	97,939	Mar 19 08:57 PM
Shulman Joseph	Chief Technical Officer	Mar 19 '24	Sale	39.22	15,515	608,498	18,265	Mar 19 08:56 PM
Meeker David P	President and CEO	Mar 19 '24	Sale	39.22	45,494	1,784,275	174,605	Mar 19 08:54 PM
Mazabraud Yann	EVP, Head of International	Mar 19 '24	Sale	39.22	16,000	627,520	24,495	Mar 19 08:53 PM
Lee Jennifer Kayden	EVP, Head of North America	Mar 19 '24	Sale	39.22	15,515	608,498	25,087	Mar 19 08:52 PM
Cramer Pamela J.	Chief Human Resources Officer	Mar 19 '24	Sale	39.22	15,515	608,498	30,005	Mar 19 08:50 PM
Shulman Joseph	Chief Technical Officer	Feb 13 '24	Sale	50.00	1,865	93,250	1,119	Feb 15 06:14 PM
Shulman Joseph	Chief Technical Officer	Feb 14 '24	Sale	50.01	1,089	54,461	30	Feb 15 06:14 PM
Smith Hunter C	Chief Financial Officer	Feb 12 '24	Sale	51.38	1,209	62,118	80,413	Feb 13 08:50 PM
Smith Hunter C	Chief Financial Officer	Feb 13 '24	Sale	49.82	709	35,322	79,704	Feb 13 08:50 PM
Mazabraud Yann	EVP, Head of International	Feb 12 '24	Sale	51.38	1,594	81,900	7,702	Feb 13 08:49 PM
Mazabraud Yann	EVP, Head of International	Feb 13 '24	Sale	49.84	957	47,697	6,745	Feb 13 08:49 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 12 '24	Sale	51.38	1,023	52,562	7,467	Feb 13 08:47 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 13 '24	Sale	49.83	615	30,645	6,852	Feb 13 08:47 PM
Shulman Joseph	Chief Technical Officer	Feb 09 '24	Option Exercise	21.38	69,190	1,479,282	74,460	Feb 13 08:46 PM
Shulman Joseph	Chief Technical Officer	Feb 09 '24	Sale	50.38	71,774	3,615,982	2,686	Feb 13 08:46 PM
Shulman Joseph	Chief Technical Officer	Feb 12 '24	Sale	51.38	791	40,642	3,457	Feb 13 08:46 PM
Shulman Joseph	Chief Technical Officer	Feb 13 '24	Sale	49.84	473	23,574	2,984	Feb 13 08:46 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 12 '24	Sale	51.38	696	35,760	11,770	Feb 13 08:45 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 01 '24	Sale	45.06	1,492	67,230	3,021	Feb 05 06:55 PM
Smith Hunter C	Chief Financial Officer	Feb 01 '24	Sale	45.06	1,616	72,817	75,215	Feb 05 06:54 PM
Shulman Joseph	Chief Technical Officer	Feb 01 '24	Sale	45.06	1,324	59,659	2,614	Feb 05 06:54 PM
Meeker David P	President and CEO	Feb 01 '24	Sale	45.06	4,361	196,507	121,099	Feb 05 06:53 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 01 '24	Sale	45.06	946	42,627	10,122	Feb 05 06:53 PM
Shulman Joseph	Chief Technical Officer	Dec 28 '23	Option Exercise	21.38	6,800	145,384	7,926	Dec 29 04:30 PM
Shulman Joseph	Chief Technical Officer	Dec 27 '23	Option Exercise	21.38	2,400	51,312	6,141	Dec 29 04:30 PM
Shulman Joseph	Chief Technical Officer	Dec 28 '23	Sale	50.00	7,926	396,318	0	Dec 29 04:30 PM
Shulman Joseph	Chief Technical Officer	Dec 27 '23	Sale	50.01	5,015	250,796	1,126	Dec 29 04:30 PM
Smith Hunter C	Chief Financial Officer	Dec 06 '23	Option Exercise	6.88	20,000	137,600	81,406	Dec 07 04:16 PM
Smith Hunter C	Chief Financial Officer	Dec 05 '23	Option Exercise	6.88	7,026	48,339	68,432	Dec 07 04:16 PM
Smith Hunter C	Chief Financial Officer	Dec 06 '23	Sale	40.00	20,000	800,000	61,406	Dec 07 04:16 PM
Smith Hunter C	Chief Financial Officer	Dec 05 '23	Sale	35.06	7,026	246,360	61,406	Dec 07 04:16 PM
Smith Hunter C	Chief Financial Officer	Nov 24 '23	Option Exercise	6.88	10,974	75,501	72,380	Nov 28 04:05 PM
Smith Hunter C	Chief Financial Officer	Nov 24 '23	Sale	35.02	10,974	384,336	61,406	Nov 28 04:05 PM
Shulman Joseph	Chief Technical Officer	Nov 14 '23	Option Exercise	6.80	27,890	189,652	31,631	Nov 16 04:05 PM
Shulman Joseph	Chief Technical Officer	Nov 14 '23	Sale	32.07	27,890	894,329	3,741	Nov 16 04:05 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 14 '23	Option Exercise	6.80	12,030	81,804	13,677	Nov 16 04:05 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 14 '23	Sale	32.01	13,677	437,819	0	Nov 16 04:05 PM
Smith Hunter C	Chief Financial Officer	Nov 14 '23	Option Exercise	6.88	12,000	82,560	73,406	Nov 16 04:05 PM
Smith Hunter C	Chief Financial Officer	Nov 14 '23	Sale	30.38	12,000	364,573	61,406	Nov 16 04:05 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 08 '23	Option Exercise	6.80	5,712	38,842	7,359	Nov 13 05:44 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 09 '23	Option Exercise	6.80	3,438	23,378	5,085	Nov 13 05:44 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 08 '23	Sale	28.90	5,712	165,104	1,647	Nov 13 05:44 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 09 '23	Sale	27.69	3,438	95,183	1,647	Nov 13 05:44 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 03 '23	Option Exercise	6.80	80	544	1,727	Nov 07 06:17 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 03 '23	Sale	28.00	80	2,240	1,647	Nov 07 06:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RYTM

Rhythm Pharmaceuticals Inc.

Upgrade your FINVIZ experience